



(51) International Patent Classification:

C07D 213/82 (2006.01) **C07D 471/10** (2006.01)
C07D 295/04 (2006.01) **A61K 31/4427** (2006.01)
C07D 401/12 (2006.01) **A61K 31/501** (2006.01)
C07D 401/14 (2006.01) **A61K 31/5377** (2006.01)
C07D 405/12 (2006.01) **A61P 3/10** (2006.01)
C07D 409/12 (2006.01) **A61P 9/10** (2006.01)
C07D 413/12 (2006.01)

(21) International Application Number:

PCT/US2011/046019

(22) International Filing Date:

29 July 2011 (29.07.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/368,928 29 July 2010 (29.07.2010) US

(71) **Applicant** (for all designated States except US): **RIGEL PHARMACEUTICALS, INC.** [US/US]; 1180 Veterans Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **GOFF, Dane** [US/US]; 77 Markham Avenue, Redwood City, CA 94063 (US). **PAYAN, Donald** [US/US]; 24 Windsor Drive, Hillsborough, CA 94010 (US). **SINGH, Rajinder** [US/US]; 1832 Hillman Avenue, Belmont, CA 94002 (US). **SHAW, Simon** [GB/US]; 1232 19th Street, Unit 10, Oakland, CA 94607 (US). **CARROLL, David** [US/US]; 87 Dolores Street, Apt. 105, San Francisco, CA 94103 (US). **HITOSHI, Yasumichi** [JP/US]; 331 Cal-lippe Court, Brisbane, CA 94005 (US).

(74) **Agent:** **SUGGS, James, V.**; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME



(57) **Abstract:** Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by "B", T, R³, R⁴, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.